<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749745</url>
  </required_header>
  <id_info>
    <org_study_id>202006-003</org_study_id>
    <nct_id>NCT04749745</nct_id>
  </id_info>
  <brief_title>Effects of L-theanine on Motor Cortex Excitability in Healthy Subjects: A Paired-Pulse TMS Study</brief_title>
  <official_title>Effects of Single-dose L-theanine on Motor Cortex Excitability in Healthy Subjects: A Double-blinded, Randomized Order, Cross-over Paired-Pulse Transcranial Magnetic Stimulation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major depressive disorder (MDD) is a serious mental illness and the leading cause of&#xD;
      disability worldwide. New pharmacotherapeutic agents with complementary neurobiological&#xD;
      mechanism and better side effect profile are of great needs. In addition to the monoamine&#xD;
      system, the glutamatergic system plays a crucial role in MDD.&#xD;
&#xD;
      L-theanine (N5-ethyl-L-glutamine) is the primary psychoactive component uniquely in green&#xD;
      tea. Preclinical studies have demonstrated anti-depressant effect of L-theanine in rodents&#xD;
      and provided evidences for its pharmacological properties of N-methyl-D-aspartate (NMDA) and&#xD;
      gamma-aminobutyric acid (GABA) agonism. Yet these effects have not been proven in humans.&#xD;
      Only one open-label clinical trial has studied and supported antidepressant effects of&#xD;
      L-theanine in MDD patients. We propose using pair-pulse transcranial magnetic stimulation&#xD;
      (ppTMS) to probe how L-theanine may manipulate the glutamatergic and GABA systems in the&#xD;
      frontal region by changing cortical excitability first in healthy subjects. We plan to&#xD;
      investigate the neurobiological effects of L-theanine in healthy subjects first.&#xD;
&#xD;
      Granted that the first phase pilot trial provides neurophysiological evidence of L-theanine&#xD;
      on motor cortex excitability in human subjects, next phases of studies on L-theanine in MDD&#xD;
      patients cortical excitability could be justified.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Significance:&#xD;
&#xD;
      Major depressive disorder (MDD) is a serious mental illness and the leading cause of&#xD;
      disability worldwide. Although many antidepressants acting on synaptic monoamine levels have&#xD;
      been used as the first-line drug treatment for MDD, around one third of MDD are&#xD;
      pharmacologically resistant. Side effects of these medications impose additional hardship on&#xD;
      adherence and further affect treatment outcome. New pharmacotherapeutic agents with&#xD;
      complementary neurobiological mechanism and better side effect profile are of great needs. In&#xD;
      addition to the monoamine system, the glutamatergic system plays a crucial role in MDD.&#xD;
&#xD;
      L-theanine (N5-ethyl-L-glutamine) is the primary psychoactive component uniquely in green&#xD;
      tea. Epidemiological studies support that green tea consumption is an independent factor&#xD;
      associated with lower prevalence of depression. Preclinical studies have demonstrated anti-&#xD;
      depressant effect of L-theanine in rodents and provided evidences for its pharmacological&#xD;
      properties of N-methyl-D-aspartate (NMDA) and gamma-aminobutyric acid (GABA) agonism. Yet&#xD;
      these effects have not been proven in humans. Only one open-label clinical trial has studied&#xD;
      and supported antidepressant effects of L-theanine in MDD patients. We propose using&#xD;
      pair-pulse transcranial magnetic stimulation (ppTMS) to probe how L-theanine may manipulate&#xD;
      the glutamatergic and GABA systems in the frontal region by changing cortical excitability&#xD;
      first in healthy subjects. ppTMS is a well-established technique to investigate frontal motor&#xD;
      cortical excitability mediated by the inter-neuron NMDA and GABA receptors. Specific changes&#xD;
      of ppTMS measures, including impaired short-term and long-term intracortical inhibition&#xD;
      (SICI, mediated by GABA-A receptor; LICI, mediated by GABA-B receptor) and intracortical&#xD;
      facilitation (ICF, mediated by NMDA receptor), have been demonstrated in MDD. Using this&#xD;
      technique, we plan to investigate the neurobiological effects of L-theanine in healthy&#xD;
      subjects first.&#xD;
&#xD;
      Granted that the first phase pilot trial provides neurophysiological evidence of L-theanine&#xD;
      on motor cortex excitability in human subjects, next phases of studies on L-theanine in MDD&#xD;
      patients cortical excitability could be justified. This will lay foundation for further&#xD;
      exploration of L-theanine's potential as an augmenting agent for MDD in a placebo- controlled&#xD;
      design.&#xD;
&#xD;
      Aims and Hypothesis:&#xD;
&#xD;
      Given the potential NMDA and GABA agonistic effects of L-theanine, we hypothesize that it&#xD;
      increases intracortical inhibition and facilitation through enhancement of NMDA- and&#xD;
      GABA-receptor mediated neurotransmission, in healthy subjects (N=10 to complete study).&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      Double-blinded, Randomized-order, Cross-over placebo-controlled to evaluate acute effect of&#xD;
      single-dose L-theanine on motor cortex excitability by ppTMS in 10 healthy subjects.&#xD;
&#xD;
      Dose of L-theanine or placebo is 400mg. At baseline, subjects will be randomized to L-&#xD;
      theanine or placebo group, then receive ppTMS protocol before drug administration. The ppTMS&#xD;
      protocol is repeated after 30min of administration. Then subjects will return to clinic after&#xD;
      1 week free of any medications and repeat the above protocol with the second drug condition.&#xD;
      Visual analog scale will be used to evaluate psychosomatic symptoms and wellbeing of the&#xD;
      subjects pre- and post-each drug administration.&#xD;
&#xD;
      Data Analytic Plan:&#xD;
&#xD;
      Wilcoxon test will be used to compare the baseline-to-post-drug means of SICI, LICI and ICF&#xD;
      measures. Prespecified covariates include age, sex, handedness, level of fatigue will be&#xD;
      analyzed in linear regression model. The time-condition relationship with continuous&#xD;
      dependent variables of ICI and ICF values will be evaluated by Mixed Effect Model. Two- sided&#xD;
      P value &lt; 0.05 is considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a pilot study, investigating the effects of single dose L-theanine in Healthy subjects, to further assess the validity and feasibility to study this compound in patient population.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of Motor Cortex Excitability Measures by ppTMS</measure>
    <time_frame>Before and 30 minutes after each drug administration (no long-term follow up as this is a study on acute effect of a single-dose agent).</time_frame>
    <description>The changes of Short-interval Intracortical Inhibition (SICI), Intracortical Facilitation (ICF), and Long-interval Intracortical Inhibition (LICI) before and 30 minutes after each drug administration.&#xD;
SICI, ICF and LICI are paired-pulse TMS (ppTMS)-EMG outcome measures that assess the activity of motor cortex GABA-A, NMDA and GABA-B interneurons, respectively. They are measured by the ratio between the peak-to-peak amplitude of motor-evoked potential (MEP) elicited by a testing TMS pulse (120% of the intensity of the resting motor threshold, following a conditioning pulse at different inter-stimuli interval, 2-5 milliseconds for SICI, 10-20 milliseconds for ICF, 100-200 milliseconds for LICI) and the peak-to-peak MEP amplitude elicited by a single pulse (120% of the intensity of the resting motor threshold).&#xD;
The baseline-to-post-drug change of SICI, ICF and LICI elicited by L-theanine will be compared to that elicited by placebo within each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change of Visual Analog Scale (VAS)</measure>
    <time_frame>Throughout each session; each session lasts up to 3 hours; 2 sessions for each subject. The 2 sessions are 3-7 days apart.</time_frame>
    <description>VAS is a quick scale to assess and track how the participant subjectively feels through out each study session, e.g. anxiety, depression, excitement, etc. The score for each word ranges from &quot;0&quot; being the least in your life and &quot;100&quot; being the most in your life. It takes 3-4 minutes to complete each VAS, and there are 4 takes of VAS during each session. The outcome measure is the change of VAS throughout the 4 time points: 1) before the baseline ppTMS procedure; 2) before drug administration; 3) 30 minutes after drug administration; 4) before discharge from the session, during the session.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cortical Excitability</condition>
  <condition>Psychiatric Disorder</condition>
  <arm_group>
    <arm_group_label>L-Theanine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-theanine</intervention_name>
    <description>The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.</description>
    <arm_group_label>L-Theanine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.</description>
    <arm_group_label>L-Theanine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult, aged between 18 and 65 years old;&#xD;
&#xD;
          2. Able to read/speak English and give informed consent&#xD;
&#xD;
          3. No current or history of Axis I psychiatric disorders by DSM-5.&#xD;
&#xD;
          4. Free of psychotropic medication use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant acute or chronic neurological or medical disorder or condition&#xD;
             that increases risk for seizure with TMS;&#xD;
&#xD;
          2. History of alcohol use disorder, nicotine dependence, adjustment disorder;&#xD;
&#xD;
          3. History of allergic reactions to L-theanine or green tea;&#xD;
&#xD;
          4. Pregnancy;&#xD;
&#xD;
          5. Unable/unwilling to abstain from nutraceutical supplements and psychotropic agents&#xD;
             during participation in the study&#xD;
&#xD;
          6. Unable/ unwillingness to refrain from recreational substance use (e.g. alcohol or&#xD;
             marijuana) during participation in the study;&#xD;
&#xD;
          7. Meet criteria for exclusion from TMS or MRI procedures, including intracranial metal&#xD;
             implants or nonremovable ferromagnetic items in the head/neck.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University-Butler Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vuong QV, Bowyer MC, Roach PD. L-Theanine: properties, synthesis and isolation from tea. J Sci Food Agric. 2011 Aug 30;91(11):1931-9. doi: 10.1002/jsfa.4373. Epub 2011 Mar 29. Review.</citation>
    <PMID>21735448</PMID>
  </reference>
  <reference>
    <citation>Kim J, Kim J. Green Tea, Coffee, and Caffeine Consumption Are Inversely Associated with Self-Report Lifetime Depression in the Korean Population. Nutrients. 2018 Sep 1;10(9). pii: E1201. doi: 10.3390/nu10091201.</citation>
    <PMID>30200434</PMID>
  </reference>
  <reference>
    <citation>Hintikka J, Tolmunen T, Honkalampi K, Haatainen K, Koivumaa-Honkanen H, Tanskanen A, Viinamäki H. Daily tea drinking is associated with a low level of depressive symptoms in the Finnish general population. Eur J Epidemiol. 2005;20(4):359-63.</citation>
    <PMID>15971509</PMID>
  </reference>
  <reference>
    <citation>Hozawa A, Kuriyama S, Nakaya N, Ohmori-Matsuda K, Kakizaki M, Sone T, Nagai M, Sugawara Y, Nitta A, Tomata Y, Niu K, Tsuji I. Green tea consumption is associated with lower psychological distress in a general population: the Ohsaki Cohort 2006 Study. Am J Clin Nutr. 2009 Nov;90(5):1390-6. doi: 10.3945/ajcn.2009.28214. Epub 2009 Sep 30.</citation>
    <PMID>19793850</PMID>
  </reference>
  <reference>
    <citation>Wakabayashi C, Numakawa T, Ninomiya M, Chiba S, Kunugi H. Behavioral and molecular evidence for psychotropic effects in L-theanine. Psychopharmacology (Berl). 2012 Feb;219(4):1099-109. doi: 10.1007/s00213-011-2440-z. Epub 2011 Aug 23.</citation>
    <PMID>21861094</PMID>
  </reference>
  <reference>
    <citation>Egashira N, Ishigami N, Pu F, Mishima K, Iwasaki K, Orito K, Oishi R, Fujiwara M. Theanine prevents memory impairment induced by repeated cerebral ischemia in rats. Phytother Res. 2008 Jan;22(1):65-8.</citation>
    <PMID>17705146</PMID>
  </reference>
  <reference>
    <citation>Lardner AL. Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders. Nutr Neurosci. 2014 Jul;17(4):145-55. doi: 10.1179/1476830513Y.0000000079. Epub 2013 Nov 26. Review.</citation>
    <PMID>23883567</PMID>
  </reference>
  <reference>
    <citation>Hidese S, Ota M, Wakabayashi C, Noda T, Ozawa H, Okubo T, Kunugi H. Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiatr. 2017 Apr;29(2):72-79. doi: 10.1017/neu.2016.33. Epub 2016 Jul 11.</citation>
    <PMID>27396868</PMID>
  </reference>
  <reference>
    <citation>Paulus W, Classen J, Cohen LG, Large CH, Di Lazzaro V, Nitsche M, Pascual-Leone A, Rosenow F, Rothwell JC, Ziemann U. State of the art: Pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul. 2008 Jul;1(3):151-63. doi: 10.1016/j.brs.2008.06.002. Epub 2008 Jun 30. Review.</citation>
    <PMID>20633382</PMID>
  </reference>
  <reference>
    <citation>Radhu N, de Jesus DR, Ravindran LN, Zanjani A, Fitzgerald PB, Daskalakis ZJ. A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin Neurophysiol. 2013 Jul;124(7):1309-20. doi: 10.1016/j.clinph.2013.01.014. Epub 2013 Feb 26.</citation>
    <PMID>23485366</PMID>
  </reference>
  <reference>
    <citation>Bajbouj M, Lisanby SH, Lang UE, Danker-Hopfe H, Heuser I, Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry. 2006 Mar 1;59(5):395-400. Epub 2005 Sep 28.</citation>
    <PMID>16197927</PMID>
  </reference>
  <reference>
    <citation>Lefaucheur JP, Lucas B, Andraud F, Hogrel JY, Bellivier F, Del Cul A, Rousseva A, Leboyer M, Paillère-Martinot ML. Inter-hemispheric asymmetry of motor corticospinal excitability in major depression studied by transcranial magnetic stimulation. J Psychiatr Res. 2008 Apr;42(5):389-98. Epub 2007 Apr 20.</citation>
    <PMID>17449060</PMID>
  </reference>
  <reference>
    <citation>Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry. 2010 Mar 1;67(5):458-64. doi: 10.1016/j.biopsych.2009.09.025. Epub 2009 Nov 17.</citation>
    <PMID>19922906</PMID>
  </reference>
  <reference>
    <citation>Jeng JS, Li CT, Lin HC, Tsai SJ, Bai YM, Su TP, Chang YW, Cheng CM. Antidepressant-resistant depression is characterized by reduced short- and long-interval cortical inhibition. Psychol Med. 2020 Jun;50(8):1285-1291. doi: 10.1017/S0033291719001223. Epub 2019 Jun 3.</citation>
    <PMID>31155020</PMID>
  </reference>
  <reference>
    <citation>Ziemann U, Chen R, Cohen LG, Hallett M. Dextromethorphan decreases the excitability of the human motor cortex. Neurology. 1998 Nov;51(5):1320-4.</citation>
    <PMID>9818853</PMID>
  </reference>
  <reference>
    <citation>Schwenkreis P, Witscher K, Janssen F, Addo A, Dertwinkel R, Zenz M, Malin JP, Tegenthoff M. Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett. 1999 Aug 6;270(3):137-40.</citation>
    <PMID>10462113</PMID>
  </reference>
  <reference>
    <citation>Di Lazzaro V, Oliviero A, Saturno E, Dileone M, Pilato F, Nardone R, Ranieri F, Musumeci G, Fiorilla T, Tonali P. Effects of lorazepam on short latency afferent inhibition and short latency intracortical inhibition in humans. J Physiol. 2005 Apr 15;564(Pt 2):661-8. Epub 2005 Feb 17.</citation>
    <PMID>15718269</PMID>
  </reference>
  <reference>
    <citation>Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011 Jan;72(1):34-42. doi: 10.4088/JCP.09m05324gre. Epub 2010 Nov 30.</citation>
    <PMID>21208586</PMID>
  </reference>
  <reference>
    <citation>Borzelleca JF, Peters D, Hall W. A 13-week dietary toxicity and toxicokinetic study with l-theanine in rats. Food Chem Toxicol. 2006 Jul;44(7):1158-66. Epub 2006 Apr 26.</citation>
    <PMID>16759779</PMID>
  </reference>
  <reference>
    <citation>Taylor JJ, Borckardt JJ, George MS. Endogenous opioids mediate left dorsolateral prefrontal cortex rTMS-induced analgesia. Pain. 2012 Jun;153(6):1219-1225. doi: 10.1016/j.pain.2012.02.030. Epub 2012 Mar 22.</citation>
    <PMID>22444187</PMID>
  </reference>
  <reference>
    <citation>Health Quality Ontario. Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Ont Health Technol Assess Ser. 2016 Mar 1;16(5):1-66. eCollection 2016. Review.</citation>
    <PMID>27099642</PMID>
  </reference>
  <reference>
    <citation>Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012 Jul;29(7):587-96. doi: 10.1002/da.21969. Epub 2012 Jun 11.</citation>
    <PMID>22689344</PMID>
  </reference>
  <reference>
    <citation>Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.</citation>
    <PMID>25655160</PMID>
  </reference>
  <reference>
    <citation>Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009 Dec;120(12):2008-2039. doi: 10.1016/j.clinph.2009.08.016. Epub 2009 Oct 14. Review.</citation>
    <PMID>19833552</PMID>
  </reference>
  <reference>
    <citation>McClintock SM, Reti IM, Carpenter LL, McDonald WM, Dubin M, Taylor SF, Cook IA, O'Reardon J, Husain MM, Wall C, Krystal AD, Sampson SM, Morales O, Nelson BG, Latoussakis V, George MS, Lisanby SH; National Network of Depression Centers rTMS Task Group; American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: 16cs10905. doi: 10.4088/JCP.16cs10905.</citation>
    <PMID>28541649</PMID>
  </reference>
  <reference>
    <citation>Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998 Jan;108(1):1-16.</citation>
    <PMID>9474057</PMID>
  </reference>
  <reference>
    <citation>Gomez-Ramirez M, Kelly SP, Montesi JL, Foxe JJ. The effects of L-theanine on alpha-band oscillatory brain activity during a visuo-spatial attention task. Brain Topogr. 2009 Jun;22(1):44-51. doi: 10.1007/s10548-008-0068-z. Epub 2008 Oct 9.</citation>
    <PMID>18841456</PMID>
  </reference>
  <reference>
    <citation>Gomez-Ramirez M, Higgins BA, Rycroft JA, Owen GN, Mahoney J, Shpaner M, Foxe JJ. The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin Neuropharmacol. 2007 Jan-Feb;30(1):25-38.</citation>
    <PMID>17272967</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <results_first_submitted>July 1, 2021</results_first_submitted>
  <results_first_submitted_qc>August 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>L-theanine</keyword>
  <keyword>Cortical Excitability</keyword>
  <keyword>NMDA</keyword>
  <keyword>GABA</keyword>
  <keyword>Paired-Pulse TMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To protect subject confidential information.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04749745/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT04749745/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We screened and enrolled 11 subjects altogether. 10 subjects in total completed the study. As this is a cross-over study, so each arm has 10 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>L-Theanine First, Then Placebo</title>
          <description>Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.&#xD;
L-theanine: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.&#xD;
Placebo: The subject will receive ppTMS procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse is delivered, the EMG over the abductor pollicis brevis will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then L-Theanine</title>
          <description>Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.&#xD;
L-theanine: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.&#xD;
Placebo: The subject will receive ppTMS procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface EMG. The ppTMS procedure is administered by a TMS stimulator controlled a software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse is delivered by the coil, the EMG over the abductor pollicis brevis will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a cross-over study, therefore, the total number of subjects is 10.</population>
      <group_list>
        <group group_id="B1">
          <title>L-Theanine and Placebo Cross-over in All Subjects</title>
          <description>Subject will receive 400mg single dose of L-theanine or Placebo, by oral ingestion with water. After 72 hours washout period, the same subject will then receive 400mg single dose of Placebo or L-theanine (opposite condition from the first dose). The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded. All subjects receive both conditions of drugs.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Handedness (Right)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Multilingual</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years of Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Sleep Hours</title>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily Coffee Drinker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change of Motor Cortex Excitability Measures by ppTMS</title>
        <description>The changes of Short-interval Intracortical Inhibition (SICI), Intracortical Facilitation (ICF), and Long-interval Intracortical Inhibition (LICI) before and 30 minutes after each drug administration.&#xD;
SICI, ICF and LICI are paired-pulse TMS (ppTMS)-EMG outcome measures that assess the activity of motor cortex GABA-A, NMDA and GABA-B interneurons, respectively. They are measured by the ratio between the peak-to-peak amplitude of motor-evoked potential (MEP) elicited by a testing TMS pulse (120% of the intensity of the resting motor threshold, following a conditioning pulse at different inter-stimuli interval, 2-5 milliseconds for SICI, 10-20 milliseconds for ICF, 100-200 milliseconds for LICI) and the peak-to-peak MEP amplitude elicited by a single pulse (120% of the intensity of the resting motor threshold).&#xD;
The baseline-to-post-drug change of SICI, ICF and LICI elicited by L-theanine will be compared to that elicited by placebo within each subject.</description>
        <time_frame>Before and 30 minutes after each drug administration (no long-term follow up as this is a study on acute effect of a single-dose agent).</time_frame>
        <population>This is a cross-over study, therefore each subject will receive the drug conditions in both arms. The outcomes will be compared using Wilcoxon Signed-rank test to see if L-theanine elicits different changes of SICI, ICF or LICI within each individual than placebo does.</population>
        <group_list>
          <group group_id="O1">
            <title>L-Theanine</title>
            <description>Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.&#xD;
The baseline-to-post-drug change of SICI, ICF and LICI elicited by L-theanine will be compared to that elicited by placebo within each subject.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.&#xD;
The baseline-to-post-drug change of SICI, ICF and LICI elicited by L-theanine will be compared to that elicited by placebo within each subject.</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of Motor Cortex Excitability Measures by ppTMS</title>
          <description>The changes of Short-interval Intracortical Inhibition (SICI), Intracortical Facilitation (ICF), and Long-interval Intracortical Inhibition (LICI) before and 30 minutes after each drug administration.&#xD;
SICI, ICF and LICI are paired-pulse TMS (ppTMS)-EMG outcome measures that assess the activity of motor cortex GABA-A, NMDA and GABA-B interneurons, respectively. They are measured by the ratio between the peak-to-peak amplitude of motor-evoked potential (MEP) elicited by a testing TMS pulse (120% of the intensity of the resting motor threshold, following a conditioning pulse at different inter-stimuli interval, 2-5 milliseconds for SICI, 10-20 milliseconds for ICF, 100-200 milliseconds for LICI) and the peak-to-peak MEP amplitude elicited by a single pulse (120% of the intensity of the resting motor threshold).&#xD;
The baseline-to-post-drug change of SICI, ICF and LICI elicited by L-theanine will be compared to that elicited by placebo within each subject.</description>
          <population>This is a cross-over study, therefore each subject will receive the drug conditions in both arms. The outcomes will be compared using Wilcoxon Signed-rank test to see if L-theanine elicits different changes of SICI, ICF or LICI within each individual than placebo does.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SICI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.059" spread="0.028"/>
                    <measurement group_id="O2" value="0.005" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ICF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.073"/>
                    <measurement group_id="O2" value="-0.341" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LICI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" spread="0.100"/>
                    <measurement group_id="O2" value="-0.068" spread="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change of Visual Analog Scale (VAS)</title>
        <description>VAS is a quick scale to assess and track how the participant subjectively feels through out each study session, e.g. anxiety, depression, excitement, etc. The score for each word ranges from &quot;0&quot; being the least in your life and &quot;100&quot; being the most in your life. It takes 3-4 minutes to complete each VAS, and there are 4 takes of VAS during each session. The outcome measure is the change of VAS throughout the 4 time points: 1) before the baseline ppTMS procedure; 2) before drug administration; 3) 30 minutes after drug administration; 4) before discharge from the session, during the session.</description>
        <time_frame>Throughout each session; each session lasts up to 3 hours; 2 sessions for each subject. The 2 sessions are 3-7 days apart.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours after administration of each drug condition (single dose of L-theanine or placebo).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>L-Theanine</title>
          <description>Subject will receive 400mg single dose of L-theanine, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subject will receive 400mg single dose of matching Placebo, by oral ingestion with water. The capsules are prepared and dispensed by hospital pharmacy, with the investigator and participant both blinded.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>This was associated with the testing method (transcranial magnetic stimulation) before data collection. The subject recovered back to baseline mental status quickly from the syncope and did not need emergent medical care or hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shiwen Yuan</name_or_title>
      <organization>Butler Hospital</organization>
      <phone>2025783000</phone>
      <email>shiwen_yuan@brown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

